1Paulson TG,Galipeau PC,Xu L. p16 mutatio spectrum in the premalignant condition Barrett′s esophagus[J].PLoS One,2008,(11):e3809.
2Cronin J,McAdam E,Danikas A. Epidermal growth factor re-ceptor(EGFR)is overexpressed in high-grade dysplasia and adeno-carcinoma of the esophagus and may represent a biomarker of histo-logical progression in Barrett′s esophagus(BE)[J].{H}American Journal of Gastroenterology,2011,(01):46-56.
3Becker L,Huang Q,Mashimo H. Lgr5,an intestinal stem cell mark-er,is abnormally expressed in Barrett′s esophagus and esophageal adenocarcinoma[J].{H}Disease of The Esophagus,2010,(02):168-174.
4Türkmen I覶;Bassüllü N;Uraz S.CDX2,COX2 and MUC2 ex-pressions in Barrett′s esophagus:can they be useful in determination of the dysplasia Turk Patoloji Derg[J],2012(03):251-258.
5Weimann A,Rieger A,Zimmermann M. Comparison of six immunohistochemical markers for the histologic diagnosis of neo-plasia in Barrett′s esophagus[J].{H}VIRCHOWS ARCHIV-AN INTERNATIONAL Journal OF PATHOLOGY,2010,(05):537-545.
6Weimann A,Zimmermann M,Gross M. CDX2 and LI-cad-herin expression in esophageal mucosa:use of both markers can fa-cilitate the histologic diagnosis of Barrett′s esophagus and carcino-ma[J].{H}INTERNATIONAL JOURNAL OF SURGICAL PATHOLOGY,2010,(05):330-337.
7Ferguson HR,Wild CP,Anderson LA. Cyclooxygenase-2 and inducible nitric oxide synthase gene polymorphisms and risk of re-flux esophagitis,Barrett′s esophagus,and esophageal adenocarcino-ma[J].Cancer Epidemiol Biomakers Prev,2008,(03):727-731.
8Hu X,Kuhn JR. Actin filament attachments for sustained motility in vitro are maintained by filameng bundling[J].PloS One,2012,(02):e31385.
9Hashimoto Y,Kim DJ,Adams JC. The roles of fascina in health and disease[J].{H}Journal of Pathology,2011,(03):289-300.
